Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: Novartis Pharmaceuticals UK Limited, 2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ, United Kingdom
MAXIDEX 0.1% w/v, eye drops, suspension.
| Pharmaceutical Form |
|---|
|
Eye drops, suspension. |
Dexamethasone 0.1% w/v.
Excipient with known effect in suspension:
Benzalkonium Chloride 0.01% w/v.
For the full list excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Dexamethasone |
Dexamethasone is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. It has an approximately 7 times greater anti-inflammatory potency than prednisolone, another commonly prescribed corticosteroid. At high doses it reduces the immune response. |
| List of Excipients |
|---|
|
Sodium phosphate |
Drop-Tainer – 5ml and 10ml Natural Low Density Polyethylene Bottles and Plugs.
Polystyrene or Polypropylene cap.
Novartis Pharmaceuticals UK Limited, 2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ, United Kingdom
PL 00101/0999
28/09/1990 / 17/09/2003
| Drug | Countries | |
|---|---|---|
| MAXIDEX | Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, France, Hong Kong, Croatia, Ireland, Lithuania, Malta, Nigeria, New Zealand, Romania, Singapore, Turkey, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
